<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: adversely", fill: "#e9692c"},
{source: "3: adversely", target: "3: operations as", fill: "#e9692c"},
{source: "3: adversely", target: "4: dependent on", fill: "#ffb300"},
{source: "4: dependent on", target: "4: continued successful", fill: "#ffb300"},
{source: "4: continued successful", target: "4: commercialization", fill: "#ffb300"},
{source: "4: dependent on", target: "13: must continually", fill: "#3d0c02"},
{source: "13: must continually", target: "13: labeling advertising", fill: "#3d0c02"},
{source: "13: must continually", target: "18: operations", fill: "#c9a0dc"},
{source: "18: operations", target: "19: incur significant expenses over", fill: "#cf71af"},
{source: "19: incur significant expenses over", target: "19: next several years as", fill: "#cf71af"},
{source: "19: next several years as", target: "19: development efforts", fill: "#cf71af"},
{source: "19: development efforts", target: "19: postoperative", fill: "#cf71af"},
{source: "19: postoperative", target: "19: PONV and Aloxi ", fill: "#cf71af"},
{source: "19: PONV and Aloxi ", target: "19: product candidates", fill: "#cf71af"},
{source: "19: product candidates", target: "19: candidates", fill: "#cf71af"},
{source: "19: candidates", target: "19: amolimogene", fill: "#cf71af"},
{source: "19: amolimogene", target: "19: formerly known as", fill: "#cf71af"},
{source: "19: formerly known as", target: "19: commercialization", fill: "#cf71af"},
{source: "19: commercialization", target: "19: of Aloxi Gliadel Wafer Gliadel ", fill: "#cf71af"},
{source: "19: of Aloxi Gliadel Wafer Gliadel ", target: "19: additional", fill: "#cf71af"},
{source: "19: incur significant expenses over", target: "33: fluctuate significantly from period", fill: "#ff6fff"},
{source: "33: fluctuate significantly from period", target: "33: period due", fill: "#ff6fff"},
{source: "33: period due", target: "33: acceptance", fill: "#ff6fff"},
{source: "33: acceptance", target: "33: Aloxi ", fill: "#ff6fff"},
{source: "33: Aloxi ", target: "33: Gliadel ", fill: "#ff6fff"},
{source: "33: Gliadel ", target: "33: approval by", fill: "#ff6fff"},
{source: "33: approval by", target: "33: FDA for Dacogen ", fill: "#ff6fff"},
{source: "33: FDA for Dacogen ", target: "33: third parties introducing competing products", fill: "#ff6fff"},
{source: "33: third parties introducing competing products", target: "33: competing products", fill: "#ff6fff"},
{source: "33: competing products", target: "33: announcements", fill: "#ff6fff"},
{source: "33: announcements", target: "33: clinical trials", fill: "#ff6fff"},
{source: "33: clinical trials", target: "33: product candidates", fill: "#ff6fff"},
{source: "33: product candidates", target: "33: drug discovery", fill: "#ff6fff"},
{source: "33: drug discovery", target: "33: expenditures", fill: "#ff6fff"},
{source: "33: expenditures", target: "33: promote additional products", fill: "#ff6fff"},
{source: "33: promote additional products", target: "33: acquisitions", fill: "#ff6fff"},
{source: "33: acquisitions", target: "33: availability", fill: "#ff6fff"},
{source: "33: availability", target: "33: marketing expenditures", fill: "#ff6fff"},
{source: "33: marketing expenditures", target: "33: royalty revenues", fill: "#ff6fff"},
{source: "33: royalty revenues", target: "33: third party payer", fill: "#ff6fff"},
{source: "33: third party payer", target: "33: government reimbursement", fill: "#ff6fff"},
{source: "33: government reimbursement", target: "33: generic products", fill: "#ff6fff"},
{source: "33: generic products", target: "33: compete with", fill: "#ff6fff"},
{source: "33: compete with", target: "33: proprietary products", fill: "#ff6fff"},
{source: "33: fluctuate significantly from period", target: "35: December ", fill: "#922724"},
{source: "35: December ", target: "35: inprocess research", fill: "#922724"},
{source: "35: inprocess research", target: "35: development", fill: "#922724"},
{source: "35: development", target: "35: acquisitions compared", fill: "#922724"},
{source: "35: December ", target: "START_HERE", fill: "#922724"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Censorship</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><font color="blue">MGI PHARMA </font>INC      Item 1A Risk Factors     Sales of Aloxi injection (“Aloxi”) account for a <font color="blue">significant</font> portion of our     <font color="blue"><font color="blue">product revenue</font>s</font></td>
    </tr>
    <tr>
      <td>Our business is <font color="blue"><font color="blue">dependent</font> on</font> the <font color="blue">commercial success</font> of     Aloxi</td>
    </tr>
    <tr>
      <td>If any factor <font color="blue">adversely</font> affects sales of Aloxi, we may be unable to     continue our <font color="blue"><font color="blue">operations</font> as</font> planned</td>
    </tr>
    <tr>
      <td>The  success  of our business is <font color="blue"><font color="blue">dependent</font> on</font> the <font color="blue">continued successful</font>     <font color="blue">commercialization</font>  of  Aloxi</td>
    </tr>
    <tr>
      <td>Aloxi  sales represented 91 percent and     83 percent of our total <font color="blue">product sales</font> and 89 and 81 percent of our total     revenue  for  the years ended <font color="blue">December </font>31, 2005 and <font color="blue">December </font>31, 2004,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Any factor <font color="blue">adversely</font> <font color="blue">affecting</font> sales of Aloxi could cause our     <font color="blue"><font color="blue">product revenue</font>s</font> to decrease and our stock price to decline <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Aloxi is <font color="blue">relatively new</font> to the market, when compared to its <font color="blue"><font color="blue">competitor</font>s</font>, and     its long-term <font color="blue">acceptance</font> by the <font color="blue">oncology community will depend largely on</font>     our  ability  to  <font color="blue">demonstrate</font>  the  efficacy and safety of Aloxi as an     <font color="blue">alternative</font> to other therapies</td>
    </tr>
    <tr>
      <td>We cannot be certain that Aloxi <font color="blue">will provide</font>     benefits considered <font color="blue">adequate by providers</font> of <font color="blue">oncology services</font> or that     <font color="blue">enough providers will use</font> the product to ensure its <font color="blue">continued commercial</font>     success</td>
    </tr>
    <tr>
      <td>Patent protection for injectable Zofran (<font color="blue">ondansetron</font>), a <font color="blue">major competing</font>     product,  will expire in 2006</td>
    </tr>
    <tr>
      <td>This will allow for the generic 5-HT[3]     <font color="blue">inhibitors</font>, <font color="blue">which could</font> <font color="blue">negatively</font> affect sales of all branded 5-HT[3]     <font color="blue">inhibitors</font> including Aloxi</td>
    </tr>
    <tr>
      <td>The Food and Drug Administration (“FDA”) subjects an <font color="blue">approved product</font> and     its <font color="blue"><font color="blue">manufacture</font>r</font> to <font color="blue">continual <font color="blue">regulatory</font> review</font></td>
    </tr>
    <tr>
      <td>After approval and use in     an  increasing number of patients, the <font color="blue">discovery</font> of <font color="blue"><font color="blue">previously</font> unknown</font>     <font color="blue">problems with</font> a product, such as unacceptable toxicities or side effects,     may result in <font color="blue">restrictions</font> or <font color="blue">sanctions on</font> the product or <font color="blue"><font color="blue">manufacture</font>r</font> that     could  affect the <font color="blue">commercial viability</font> of the product or could require     withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Further, we <font color="blue">must continually</font>     submit any labeling, <font color="blue">advertising</font> and promotional material to the FDA for     review</td>
    </tr>
    <tr>
      <td>There is risk that the FDA <font color="blue">will prohibit use</font> of the marketing     material in the form we desire</td>
    </tr>
    <tr>
      <td><font color="blue">Unfavorable </font>outcomes resulting <font color="blue">from factors such as</font> those identified above     <font color="blue">could limit sales</font> of Aloxi or cause sales of Aloxi to decline</td>
    </tr>
    <tr>
      <td>In those     <font color="blue">circumstances</font>, our <font color="blue">stock price would decline</font> and we would have to find     <font color="blue"><font color="blue">additional</font> sources</font> of funding or scale back or <font color="blue">cease <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>If we do not have net income in the future,     we may be unable to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We expect to incur <font color="blue">significant</font> expenses over the <font color="blue">next several years as</font> we     devote substantial resources to 1) support of the <font color="blue"><font color="blue">development</font> efforts</font> of     Aloxi <font color="blue">products through</font> milestone payments to Helsinn, such as Aloxi for     post-operative nausea and vomiting (“PONV”) and Aloxi oral for CINV (“<font color="blue">Aloxi     </font>Capsules”),  2) the continued <font color="blue">development</font> of other <font color="blue">product <font color="blue">candidates</font></font>,     including Aquavan Injection (“Aquavan”), <font color="blue">amolimogene</font> (HPV E6 E7 plasmid)     (<font color="blue">formerly known as</font> ZYC101a), Saforis Powder for Oral Suspension (“Saforis”),     Dacogen Injection (“Dacogen”) and irofulven, 3) continued <font color="blue">commercialization</font>     of Aloxi, Gliadel Wafer (“Gliadel”), and our other marketed products and 4)     acquire <font color="blue">additional</font> <font color="blue">product <font color="blue">candidates</font></font> or companies</td>
    </tr>
    <tr>
      <td>Therefore, we may not     <font color="blue">generate net income on</font> a <font color="blue">consistent basis</font>, or at all, unless we are able to     <font color="blue">significant</font>ly <font color="blue">increase sales</font> of Aloxi, Gliadel, or other <font color="blue">products compared</font>     to  our current sales, and/or <font color="blue">significant</font>ly reduce the funding for our     research and <font color="blue"><font color="blue">development</font> programs</font> or commercial <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In  addition to Aloxi, to a more limited extent we <font color="blue">will also <font color="blue">depend on</font></font>     maintaining or <font color="blue">increasing <font color="blue">revenues from</font></font> Gliadel, the failure of which would     have an adverse effect on our ability to accomplish our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Prior to <font color="blue">February </font></font>2003, the FDA had <font color="blue">only approved</font> the marketing of <font color="blue">Gliadel     </font><font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>for patients who had a brain tumor surgically removed     and  had recurrent forms of a type of <font color="blue">brain cancer called glioblastoma</font>     multiforme  (“GBM”),  <font color="blue">affecting</font>  approximately 3cmam000 to 4cmam000 patients     annually</td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">February </font></font>2003, the FDA <font color="blue">granted approval</font> to also market <font color="blue">Gliadel     </font>for patients undergoing initial surgery, also known <font color="blue">as first line therapy</font>,     <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>for malignant glioma in <font color="blue">conjunction</font> with surgery and     radiation</td>
    </tr>
    <tr>
      <td>Our  ability to <font color="blue">increase sales</font> of Gliadel <font color="blue">will depend upon</font>     achieving <font color="blue">greater market penetration among</font> GBM patients and successful     marketing of Gliadel for first line therapy</td>
    </tr>
    <tr>
      <td>Even if we increase our sales     and <font color="blue">marketing efforts</font>, such increases may not result in <font color="blue">increased sales</font> of     Gliadel</td>
    </tr>
    <tr>
      <td>If Gliadel fails to <font color="blue">gain broader market <font color="blue">acceptance</font></font> for GBM patients     or <font color="blue">as first line therapy</font>, the revenues we receive from sales of <font color="blue">Gliadel     </font>would be unlikely to increase</td>
    </tr>
    <tr>
      <td>Sales of our Salagen Tablets (“Salagen”) <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>are likely to     continue to decline <font color="blue">significant</font>ly for <font color="blue">subsequent periods</font> because generic     <font color="blue">pilocarpine hydrochloride tablets</font> were <font color="blue">introduced into</font> the <font color="blue"><font color="blue">United States</font> </font>in     <font color="blue">December </font>2004</td>
    </tr>
    <tr>
      <td>Beginning in <font color="blue">December </font>2004, generic 5 milligram pilocarpine hydrochloride     <font color="blue">tablets entered</font> the <font color="blue"><font color="blue">United States</font> </font>markets where Salagen competes</td>
    </tr>
    <tr>
      <td>Sales of     Salagen declined <font color="blue">significant</font>ly in 2005 to dlra9dtta9 million from our 2004 sales     of  dlra29dtta3 million  in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Due to <font color="blue">competition</font> from these     generics, and as a result of the cessation of our <font color="blue">marketing efforts</font> of     Salagen, we expect <font color="blue">revenues from</font> Salagen to continue to decrease</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________           Our operating results may fluctuate <font color="blue">significant</font>ly, which may <font color="blue">adversely</font>     affect our stock price</td>
    </tr>
    <tr>
      <td>If  our operating results do not meet the <font color="blue">expectations</font> of investors or     <font color="blue">securities analysts</font>, our <font color="blue">stock price may decline</font></td>
    </tr>
    <tr>
      <td>Our operating results may     fluctuate <font color="blue">significant</font>ly from period to <font color="blue">period due</font> to a variety of factors     including:       •   the <font color="blue">acceptance</font> of, and demand for, Aloxi;         •   changing demand for our other products, including Gliadel;         •   <font color="blue">approval by</font> the FDA for Dacogen;         •   <font color="blue"><font color="blue">third parties</font> introducing <font color="blue">competing products</font></font>;         •   <font color="blue"><font color="blue">announcement</font>s</font> regarding the results of events relating to or results     of the <font color="blue">clinical trials</font> for our products or <font color="blue">product <font color="blue">candidates</font></font>;         •   the pace and breadth of our drug <font color="blue">discovery</font> and <font color="blue"><font color="blue">development</font> programs</font>;          •   <font color="blue"><font color="blue">expenditure</font>s</font> we incur to identify, acquire, license, develop or     promote <font color="blue">additional</font> products;         •   <font color="blue"><font color="blue">expenditure</font>s</font> we incur and assume in business <font color="blue"><font color="blue">acquisition</font>s</font>;         •   <font color="blue">availability</font> of product supply from third-party <font color="blue"><font color="blue">manufacture</font>r</font>s;         •   changes in sales and marketing <font color="blue"><font color="blue">expenditure</font>s</font>;         •   the timing of licensing and <font color="blue">royalty revenues</font>;         •   <font color="blue"><font color="blue">third party</font> payer</font> and <font color="blue"><font color="blue">government</font> <font color="blue">reimbursement</font></font> for our products; and         •   the cost of <font color="blue">competing products</font>, including the cost of <font color="blue">generic products</font>     that <font color="blue">compete with</font> our <font color="blue"><font color="blue">proprietary</font> products</font></td>
    </tr>
    <tr>
      <td>For  the  year  ended  <font color="blue">December </font>31,  2005,  we  reported  net  loss of     dlra132dtta4 million, including an estimated dlra156dtta9 million of acquired in-process     research and <font color="blue"><font color="blue">development</font> expense</font> related to the Guilford <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>For     the year ended <font color="blue">December </font>31, 2004, we reported a net loss of dlra85dtta7 million     inclusive of dlra83dtta1 million of acquired in-process research and <font color="blue">development</font>     expense related to <font color="blue"><font color="blue">acquisition</font>s</font>, compared to a net loss of dlra61dtta9 million for     the year ended <font color="blue">December </font>31, 2003</td>
    </tr>
    <tr>
      <td><font color="blue">Variations </font>in the timing of our future     revenues and <font color="blue">expenses could</font> cause <font color="blue">significant</font> <font color="blue">fluctuations</font> in our operating     results from period to period and may result in <font color="blue"><font color="blue">unanticipated</font> earnings</font>     shortfalls or losses</td>
    </tr>
    <tr>
      <td>Because of these <font color="blue">fluctuations</font>, it is possible that our     operating results for a <font color="blue">particular quarter</font> or <font color="blue">quarters will</font> not meet the     <font color="blue">expectations</font> of <font color="blue">public market analysts</font> and investors, causing the market     price of our <font color="blue">common stock</font> to decrease</td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">trading price</font> of our     <font color="blue">common stock</font> during the period of January 1, 2003 to <font color="blue">December </font>31, 2005     ranged from dlra3dtta43 to dlra34dtta49</td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">effective</font> tax rate</font>, if any, may vary <font color="blue">significant</font>ly from period to     period,  <font color="blue">especially within</font> the <font color="blue">first few years</font> of <font color="blue">becoming profitable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increases </font>in our <font color="blue"><font color="blue">effective</font> tax rate</font> would have a negative effect on our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have had no or <font color="blue">minimal provision</font> for <font color="blue">income tax expense</font> for a number of     years due to a history of incurring <font color="blue">significant</font> losses</td>
    </tr>
    <tr>
      <td>Our ability to     achieve profitable <font color="blue">operations</font> is <font color="blue"><font color="blue">dependent</font> upon</font> our <font color="blue">continued successful</font>     <font color="blue">commercialization</font>  of  Aloxi,  and therefore we continue to maintain a     valuation allowance against our <font color="blue">deferred tax assets</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">deferred tax assets</font> include the net     operating  loss  <font color="blue">carryforwards</font>  and  research  and  <font color="blue">development</font> credit     <font color="blue">carryforwards</font> acquired in the Guilford, Aesgen and Zycos <font color="blue"><font color="blue">transaction</font>s</font> all of     which are subject to ownership change <font color="blue">limitations</font> and may also be subject to     various other <font color="blue">limitations</font> on the <font color="blue">amounts utilized</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">subsequent periods</font>,     our  financial  <font color="blue">statement tax provision <font color="blue">will likely</font> approximate normal</font>     <font color="blue">statutory tax rates</font></td>
    </tr>
    <tr>
      <td>A transition to an <font color="blue"><font color="blue">effective</font> tax rate</font> that <font color="blue">approximates</font>     <font color="blue">statutory tax rates</font> could result in an increase in <font color="blue"><font color="blue">effective</font> tax rate</font> from     less  than  5 percent to approximately 35 percent</td>
    </tr>
    <tr>
      <td>An increase of this     <font color="blue">magnitude would</font> result in a <font color="blue">significant</font> reduction in our net income and net     <font color="blue">income per</font> share <font color="blue">beginning with</font> the quarter we are required to expense     approximate <font color="blue">statutory tax rates</font></td>
    </tr>
    <tr>
      <td>Even if we begin reporting an <font color="blue"><font color="blue">effective</font> tax rate</font> that <font color="blue">approximates</font> statutory     tax rates, various factors may continue to have favorable or unfavorable     effects  on our <font color="blue"><font color="blue">effective</font> tax rate</font></td>
    </tr>
    <tr>
      <td>These factors include, but are not     limited  to,  changes  in  overall  levels  of  income  before  taxes,     <font color="blue">interpretations</font> of <font color="blue">existing tax laws</font>, changes in tax laws and rates, future     levels of research and <font color="blue">development</font> spending, future                                         25       _________________________________________________________________           levels of capital <font color="blue"><font color="blue">expenditure</font>s</font>, and changes in the mix of activity in the     <font color="blue">various tax jurisdictions</font> in which we operate</td>
    </tr>
    <tr>
      <td>An increase in our <font color="blue">effective</font>     <font color="blue">tax rate would reduce</font> our net income and net <font color="blue">income per</font> share</td>
    </tr>
    <tr>
      <td><font color="blue">Clinical  </font>trials are complex and unpredictable and may be <font color="blue">difficult</font> to     complete or produce unexpected results that <font color="blue">could delay</font> or prevent our     ability to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Before obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font> for the <font color="blue">commercial sale</font> of any product     under <font color="blue">development</font>, including Aloxi PONV, Aloxi Capsules, Dacogen, Saforis,     Aquavan, <font color="blue">amolimogene</font> (HPV E6 E7 plasmid), irofulven and ZYC300, we, or our     strategic <font color="blue">collaborators</font>, must <font color="blue">demonstrate</font> through preclinical studies and     <font color="blue">clinical trials</font> that the product is safe and <font color="blue">effective</font> for use in each     <font color="blue">target <font color="blue">indication</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> collaboration with <font color="blue">Helsinn Healthcare SA </font>for     Aloxi, and for our other products other <font color="blue">collaborators</font>, <font color="blue">medical institutions</font>,     and  <font color="blue">laboratories</font>  to  conduct our clinical and <font color="blue">preclinical testing</font> in     <font color="blue">compliance with</font> good clinical and <font color="blue">laboratory practices as</font> required by the     FDA We, or our strategic <font color="blue">collaborators</font>, may <font color="blue">depend on</font> contract research     <font color="blue">organizations</font> to manage a substantial portion of the <font color="blue">medical institutions</font>     utilized to <font color="blue">conduct clinical testing</font></td>
    </tr>
    <tr>
      <td>The results <font color="blue">from preclinical animal</font>     studies and human <font color="blue">clinical trials</font> are often not predictive of the results     that will be obtained in large-scale testing</td>
    </tr>
    <tr>
      <td>Some of the results reported     from <font color="blue">clinical trials</font> are interim results and may not be predictive of future     results, including final results <font color="blue">from such trials</font>, because, among other     factors, <font color="blue">patient <font color="blue">enrollment</font></font> and the time period for <font color="blue">evaluating patient</font>     results are not complete</td>
    </tr>
    <tr>
      <td>If we, or our strategic <font color="blue">collaborators</font>, fail to     <font color="blue">adequately</font> <font color="blue">demonstrate</font> the safety and efficacy of a <font color="blue">product candidate</font>, the     FDA would not <font color="blue">provide <font color="blue">regulatory</font> approval</font> of the product</td>
    </tr>
    <tr>
      <td>The appearance of     unacceptable  toxicities, side effects or other adverse results during     <font color="blue">clinical trials</font> could interrupt, limit, delay or stop the <font color="blue">development</font> of a     <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>A number of companies in the <font color="blue"><font color="blue">pharmaceutical</font> industry</font> have     suffered  <font color="blue">significant</font> setbacks in advanced <font color="blue">clinical trials</font>, even after     experiencing promising results in <font color="blue">previous animal</font> and <font color="blue">human studies</font></td>
    </tr>
    <tr>
      <td>The time required to complete <font color="blue">clinical trials</font> is <font color="blue"><font color="blue">dependent</font> upon</font>, among other     factors, the rate of <font color="blue">patient <font color="blue">enrollment</font></font></td>
    </tr>
    <tr>
      <td>Patient <font color="blue">enrollment</font> is a function of     many factors, including:       •   the size of the <font color="blue">patient population</font>;         •   the nature of <font color="blue">clinical protocol <font color="blue">requirements</font></font>;         •   the diversion of patients to other trials or <font color="blue">marketed therapies</font>;         •   our ability to recruit and <font color="blue">manage clinical centers</font> and associated     trials;         •   the proximity of patients to <font color="blue">clinical sites</font>; and         •   the <font color="blue">patient eligibility criteria</font> for the trial</td>
    </tr>
    <tr>
      <td>Other factors, such as lack of efficacy, unacceptable toxicities, or other     adverse events, may result in <font color="blue">increased costs</font> and delays or <font color="blue">termination</font> of     <font color="blue">clinical trials</font> prior to <font color="blue">completion</font></td>
    </tr>
    <tr>
      <td>In addition, delays in <font color="blue">manufacturing</font> of     product for our <font color="blue">clinical trials</font> could impact our ability to complete our     <font color="blue">clinical trials</font> as planned</td>
    </tr>
    <tr>
      <td>Any failure to meet <font color="blue">expectations</font> related to our     <font color="blue">product <font color="blue">candidates</font></font> could <font color="blue">adversely</font> affect our stock price</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>our  product  <font color="blue">candidates</font>  such  as Dacogen, Aquavan, Saforis,     <font color="blue">amolimogene</font> (HPV E6 E7 plasmid), ZYC300 and irofulven may have <font color="blue">alternative</font>     <font color="blue">development</font> paths and we have limited resources, our focus on a particular     <font color="blue">development</font> path for these <font color="blue">product <font color="blue">candidates</font></font> may result in our failure to     <font color="blue">capitalize</font> on more profitable areas and may not result in viable products</td>
    </tr>
    <tr>
      <td>We have limited financial and product <font color="blue">development</font> resources</td>
    </tr>
    <tr>
      <td>This requires     us to focus on <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue">specific areas</font> and <font color="blue">forego opportunities</font>     with regard to other <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue">development</font> paths</td>
    </tr>
    <tr>
      <td>For example,     one of our <font color="blue">product <font color="blue">candidates</font></font>, irofulven, is in clinical and preclinical     trials for a number of <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>We expect that a portion of our product     <font color="blue"><font color="blue">development</font> efforts</font> over the <font color="blue">next several years will</font> be devoted to further     <font color="blue">development</font> of irofulven, including its <font color="blue">application</font> to the treatment of     cancers  or  sub-populations  of <font color="blue">certain types</font> of <font color="blue">cancers with</font> limited     <font color="blue">therapeutic</font>  options  <font color="blue">such as refractory cancers</font>, for which we believe     irofulven could most quickly be developed and approved for marketing</td>
    </tr>
    <tr>
      <td>We are     <font color="blue">also investigating</font> the efficacy of irofulven in <font color="blue"><font color="blue">combination</font> with</font> other     cancer  therapies</td>
    </tr>
    <tr>
      <td>While  some  of  these  trials have indicated some     <font color="blue">effective</font>ness in relation to the target medical conditions, <font color="blue">additional</font>     clinical  trials  must be conducted before <font color="blue">product registration may</font> be     requested</td>
    </tr>
    <tr>
      <td>Similar examples of <font color="blue">resource trade offs also</font> exist for our other     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In  addition, the <font color="blue">uncertainty</font> of the <font color="blue">development</font> path for a particular     <font color="blue">product candidate</font> makes it <font color="blue">difficult</font> to ascertain the <font color="blue">capital resources</font> that     will be required</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________           Our ability to achieve <font color="blue">strong revenue growth</font> for Gliadel, Aquavan, Dacogen,     and  Saforis may depend to a large extent on the results of <font color="blue">additional</font>     <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We may conduct <font color="blue">additional</font> <font color="blue">clinical trials</font> with Gliadel to provide physicians     with added clinical data and/or to expand Gliadel’s labeled <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>There is no assurance that such <font color="blue">clinical trials</font>, if any, will be successful,     or if successful, will convince the FDA that an <font color="blue">additional</font> <font color="blue">indication</font> is     warranted</td>
    </tr>
    <tr>
      <td>Also,  if  one  or more <font color="blue">additional</font> <font color="blue">clinical trials</font> are not     successful, sales of the product in its <font color="blue">current markets could</font> be <font color="blue">adversely</font>     affected and could <font color="blue">significant</font>ly <font color="blue">adversely</font> affect our ability to increase     sales of Gliadel</td>
    </tr>
    <tr>
      <td>Additionally, our ability to increase the size of the <font color="blue">potential market</font> for     Aquavan <font color="blue">will depend upon</font> our success in obtaining approval for the product     in a variety of <font color="blue">procedural sedation settings</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will likely</font> need to conduct     <font color="blue">additional</font> <font color="blue">clinical trials</font> beyond those we already have announced to do so,     and <font color="blue">such <font color="blue">trials may</font></font> not be successful or may not, in the de<font color="blue">termination</font> of     the  FDA, warrant an <font color="blue">indication</font> for Aquavan <font color="blue">larger than</font> the one we are     <font color="blue">currently attempting</font> to obtain</td>
    </tr>
    <tr>
      <td>In such cases, sales of Aquavan may not meet     our <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>We  have  initiated <font color="blue">enrollment</font> in a 480 patient acute myeloid leukemia     (“AML”) trial to expand on Dacogen’s expected labeled <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>There is     no assurance that such <font color="blue">clinical trials</font>, if any, will be successful, or if     successful,  will  convince  the  FDA that an <font color="blue">additional</font> <font color="blue">indication</font> is     warranted</td>
    </tr>
    <tr>
      <td>Additionally, Dacogen has other <font color="blue">clinical trials</font> that seek to     optimize the schedule in which the product is delivered to patients, which     may or may not be <font color="blue">enough data</font> to assure an <font color="blue">additional</font> label change to the     dosing section</td>
    </tr>
    <tr>
      <td>Our ability to achieve <font color="blue">strong revenue growth</font> for Saforis may depend to a     large  extent  on  the results of <font color="blue">additional</font> <font color="blue">clinical trials</font> that will     <font color="blue">adequately</font>  <font color="blue">characterize</font> the efficacy of Saforis in patients receiving     <font color="blue">different</font> types of cancer therapies</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">trials may</font> be undertaken     with Saforis to expand the market size in oral mucositis</td>
    </tr>
    <tr>
      <td>The outcome of     these potential <font color="blue">additional</font> <font color="blue">trials may</font> or not warrant expansion of the label     in  the view of the FDA In such a case where the FDA views that these     <font color="blue">additional</font>  trials do not warrant an <font color="blue">expanded label</font>, Saforis may under     perform in meeting our <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>European <font color="blue"><font color="blue">regulatory</font> agencies</font> have imposed <font color="blue">restrictions</font> on our ability to     import Gliadel to the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">been informed by</font> the European <font color="blue"><font color="blue"><font color="blue">regulatory</font> agency</font> responsible</font> for     overseeing the testing and release of Gliadel in the <font color="blue">European Union</font> that we     must test each sublot of Gliadel that we ship to the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td><font color="blue">Each     </font>time a lot is tested it results in the <font color="blue">destruction</font> of a portion of the lot     and  the  testing is costly</td>
    </tr>
    <tr>
      <td>This <font color="blue">requirement may</font> make it <font color="blue">commercially</font>     unfeasible to ship small sublots of Gliadel labeled for smaller <font color="blue">European     </font>markets</td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue">agree with</font> the <font color="blue"><font color="blue">regulatory</font> agency</font> to an     <font color="blue">alternative</font> method of testing and <font color="blue">releasing sublots</font> of Gliadel, we may not     be able to continue to ship Gliadel to our <font color="blue">distributors</font> for smaller <font color="blue">European     </font>markets</td>
    </tr>
    <tr>
      <td>As a result, growth in our Gliadel <font color="blue">revenue would</font> be <font color="blue">negatively</font>     affected</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a single supplier to provide us with the finished <font color="blue">drug product</font>     for <font color="blue">Aloxi and Dacogen </font>and single suppliers to provide us with the active     <font color="blue">ingredients</font> for other <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If the suppliers terminate their     <font color="blue"><font color="blue">relationship</font>s</font> with us, or are unable to fill our demand for the <font color="blue">ingredients</font>     or products, we may be unable to sell Aloxi, and the <font color="blue">development</font> of our     <font color="blue">product <font color="blue">candidates</font></font> could be delayed or if a <font color="blue">product candidate</font> is approved,     the <font color="blue">commercial launch could</font> be delayed</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">Helsinn Birex Pharmaceuticals Ltd</font></td>
    </tr>
    <tr>
      <td>as our sole and exclusive     supplier of Aloxi finished <font color="blue">drug product</font></td>
    </tr>
    <tr>
      <td><font color="blue">Helsinn Birex Pharmaceuticals Ltd</font></td>
    </tr>
    <tr>
      <td>may make <font color="blue"><font color="blue">regulatory</font> provision</font> for <font color="blue">alternate sites</font> for the <font color="blue">manufacture</font> of     Aloxi</td>
    </tr>
    <tr>
      <td>However, if our <font color="blue"><font color="blue">relationship</font> with</font> <font color="blue">Helsinn Birex Pharmaceuticals Ltd</font></td>
    </tr>
    <tr>
      <td>We rely on Pharmachemie BV as our <font color="blue">sole supplier</font> of the Dacogen finished drug     product</td>
    </tr>
    <tr>
      <td>In addition, we rely on other sole or <font color="blue">exclusive suppliers</font> for other     product  <font color="blue">candidates</font>’  finished <font color="blue">drug product</font>s</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">relationship</font> with</font>     Pharmachemie BV or another sole or <font color="blue">exclusive supplier terminates</font> or if the     supplier is unable to meet our needs for any reason, we will need to find an     <font color="blue">alternative</font> source of the <font color="blue">products supplied by</font> those companies</td>
    </tr>
    <tr>
      <td>If we are     unable to identify an <font color="blue">alternative</font> source, we may have to suspend <font color="blue">development</font>     of our <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue">delay commercial launch</font> of an <font color="blue">approved product</font>     candidate</td>
    </tr>
    <tr>
      <td>Even if we were able to procure drug <font color="blue">product from</font> an <font color="blue">alternative</font>     source, any <font color="blue">disruption</font> in <font color="blue">supply could</font> have a material adverse effect on our     ability  to  meet  our <font color="blue">development</font> goals or our ability to provide the     <font color="blue">commercial supply</font> of an <font color="blue">approved product</font> candidate, which would cause our     future <font color="blue"><font color="blue">product revenue</font>s</font> to decrease and our stock price to decline</td>
    </tr>
    <tr>
      <td>Our <font color="blue">customer base</font> is <font color="blue">highly concentrated</font></td>
    </tr>
    <tr>
      <td><font color="blue">Bankruptcy </font>or financial distress     of any of our customers would <font color="blue">adversely</font> affect our <font color="blue">financial condition</font> and     <font color="blue">fluctuations</font> in their purchases of our <font color="blue">products would</font> cause <font color="blue">volatility</font> in     our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  principal  customers,  specialty  <font color="blue">pharmaceutical</font> <font color="blue">distributors</font> and     <font color="blue">wholesalers</font>, comprise a <font color="blue">significant</font> part of the <font color="blue"><font color="blue">distribution</font> network</font> for     <font color="blue">oncology injectables</font> and <font color="blue"><font color="blue">pharmaceutical</font> products</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If     any of these <font color="blue">customers become insolvent</font> or <font color="blue">dispute payment</font> of the amount it     owes us, this would <font color="blue">adversely</font> affect our results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">fluctuations</font> in <font color="blue">customer buying patterns</font> and their     amount of inventory of our <font color="blue">products could</font> cause <font color="blue">volatility</font> in our results of     <font color="blue">operations</font> and <font color="blue">materially</font>, <font color="blue">adversely</font> impact our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________           The timing of <font color="blue">customer purchases</font> and the resulting <font color="blue">product shipments</font> have a     <font color="blue">significant</font> impact on the amount of <font color="blue">revenue from <font color="blue">product sales</font></font> that the     Company recognizes in a <font color="blue">particular period</font></td>
    </tr>
    <tr>
      <td>The  majority  of  our  sales  are  made to <font color="blue">in<font color="blue">dependent</font></font> <font color="blue">pharmaceutical</font>     <font color="blue">wholesalers</font>, including specialty oncology <font color="blue">distributors</font>, which, in turn,     resell the product to an end user (normally a clinic, hospital, <font color="blue">alternative</font>     healthcare  <font color="blue">facility</font>  or  an  <font color="blue">in<font color="blue">dependent</font></font>  pharmacy)</td>
    </tr>
    <tr>
      <td><font color="blue">Inventory </font>in the     <font color="blue">distribution</font>   channel  consists  of  inventory  held  by  <font color="blue">in<font color="blue">dependent</font></font>     <font color="blue">pharmaceutical</font> <font color="blue">wholesalers</font>, who are our <font color="blue">principal customers</font></td>
    </tr>
    <tr>
      <td>Our revenue     from  <font color="blue">product sales</font> in a <font color="blue">particular period</font> is <font color="blue">impacted by increases</font> or     <font color="blue">decreases</font> in the <font color="blue">distribution</font> channel inventory levels</td>
    </tr>
    <tr>
      <td>If <font color="blue">distribution</font>     <font color="blue">channel inventory levels increase <font color="blue">materially</font></font>, we could experience reduced     <font color="blue">sales revenue</font> in <font color="blue">subsequent periods</font> due to <font color="blue">low patient demand</font></td>
    </tr>
    <tr>
      <td>We cannot <font color="blue">significant</font>ly control or influence the <font color="blue">purchasing patterns</font> of     <font color="blue">in<font color="blue">dependent</font></font>  <font color="blue">pharmaceutical</font> <font color="blue">wholesalers</font> or end users</td>
    </tr>
    <tr>
      <td>These are highly     <font color="blue">sophisticated customers</font> that purchase our products in a <font color="blue">manner consistent</font>     with their <font color="blue">industry practices</font> and, <font color="blue">presumably based upon</font> their projected     <font color="blue">demand levels</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">incentives may impact</font> the level of inventory held     by  <font color="blue">wholesalers</font></td>
    </tr>
    <tr>
      <td>Additionally, the buying practices of the <font color="blue">wholesalers</font>     include <font color="blue">occasional speculative purchases</font> of product in excess of the current     market  demand,  at  their <font color="blue">discretion</font>, in <font color="blue">anticipation</font> of <font color="blue">future price</font>     increases</td>
    </tr>
    <tr>
      <td><font color="blue">Purchases </font>by any given customer, during any given period, may be     above or below <font color="blue">actual patient demand</font> of any of our <font color="blue">products during</font> the same     period, resulting in <font color="blue">fluctuations</font> in <font color="blue">product inventory</font> in the <font color="blue">distribution</font>     channel</td>
    </tr>
    <tr>
      <td>If <font color="blue">distribution</font> channel inventory levels substantially exceed end     user demand, we could experience <font color="blue">reduced revenue from sales</font> in subsequent     <font color="blue">periods due</font> to a reduction in end-user demand</td>
    </tr>
    <tr>
      <td>If the third-party <font color="blue"><font color="blue">manufacture</font>r</font> of Aloxi, Salagen, or <font color="blue">Aggrastat </font>or any of     our other products ceases <font color="blue">operations</font> or fails to <font color="blue"><font color="blue">comply with</font> applicable</font>     <font color="blue">manufacturing</font> <font color="blue">regulations</font>, we may not be able to <font color="blue">meet customer demand</font> in a     <font color="blue">timely manner</font>, if at all</td>
    </tr>
    <tr>
      <td>for the production of Salagen, Baxter Pharmaceuticals for the     production of Aggrastat, and other third-party <font color="blue"><font color="blue">manufacture</font>r</font>s for our other     products, other than Gliadel, which we <font color="blue">manufacture</font> ourselves</td>
    </tr>
    <tr>
      <td>We expect to     continue  to  <font color="blue">rely on others</font> to <font color="blue">manufacture</font> <font color="blue">future products</font>, including     <font color="blue">products currently</font> in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">dependence on <font color="blue">third parties</font></font> for the     <font color="blue">manufacture</font> of our products may <font color="blue">adversely</font> affect our ability to develop and     deliver <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of our products is, and will be, subject to current “good     <font color="blue">manufacturing</font> practices” <font color="blue">regulations</font> enforced by the FDA or other standards     <font color="blue">prescribed by</font> the appropriate <font color="blue"><font color="blue">regulatory</font> agency</font> in the country of use</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>is a risk that the <font color="blue"><font color="blue">manufacture</font>r</font>s of our products, including the current     <font color="blue"><font color="blue">manufacture</font>r</font>s of Aloxi, Salagen, and Aggrastat, will not <font color="blue">comply with</font> all     <font color="blue">applicable <font color="blue">regulatory</font> standards</font>, and may not be able to <font color="blue">manufacture</font> Aloxi,     Salagen,  Aggrastat, or any other product for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>If this     occurs, we might not be able to identify another third-party <font color="blue"><font color="blue">manufacture</font>r</font> on     terms acceptable to us, or any other terms</td>
    </tr>
    <tr>
      <td>Material changes to an <font color="blue">approved product</font>, such as <font color="blue">manufacturing</font> changes or     <font color="blue">additional</font> labeling claims, require further FDA review and approval</td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font>after approval is obtained, the FDA <font color="blue">may withdraw approval</font> if <font color="blue">previously</font>     <font color="blue">unknown problems</font> are discovered</td>
    </tr>
    <tr>
      <td>Further, if we, our corporate <font color="blue">collaborators</font>     or our contract <font color="blue"><font color="blue">manufacture</font>r</font>s fail to <font color="blue"><font color="blue">comply with</font> applicable</font> FDA and other     <font color="blue">regulatory</font> <font color="blue">requirements</font> at any <font color="blue">stage during</font> the <font color="blue">regulatory</font> or <font color="blue">manufacturing</font>     process, the FDA <font color="blue">may impose sanctions</font>, including:       •   marketing or <font color="blue">manufacturing</font> delays;         •   <font color="blue">warning letters</font>;         •   fines;         •   <font color="blue"><font color="blue">product recall</font>s</font> or seizures;         •   <font color="blue">injunctions</font>;         •   refusal of the FDA to review pending market approval <font color="blue">application</font>s or     <font color="blue">supplements</font> to approval <font color="blue">application</font>s;         •   total or partial suspension of production;         •   civil penalties;         •   <font color="blue">withdrawals</font> of <font color="blue">previously</font> approved marketing <font color="blue">application</font>s; or         •   criminal <font color="blue">prosecutions</font></td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________           Our business <font color="blue">strategy depends on</font> our ability to discover, acquire, license     and develop <font color="blue">product <font color="blue">candidates</font></font> and discover, acquire or <font color="blue">license approved</font>     products</td>
    </tr>
    <tr>
      <td>If we are not able to undertake these <font color="blue"><font color="blue">activities</font> <font color="blue">successfully</font></font>, we     will not be able to achieve our <font color="blue">corporate goals</font></td>
    </tr>
    <tr>
      <td>As part of our business strategy we plan to discover, acquire, license and     develop  <font color="blue">product <font color="blue">candidates</font></font> and discover, acquire and <font color="blue">license approved</font>     products  for  markets  that  we  can  <font color="blue">reach through</font> our marketing and     <font color="blue">distribution</font> channels</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in our drug <font color="blue">discovery</font> and     <font color="blue">acquisition</font> strategy, our <font color="blue"><font color="blue">stock price could</font> decline</font></td>
    </tr>
    <tr>
      <td>If we fail to discover,     obtain, develop and <font color="blue">successfully</font> <font color="blue">commercialize</font> <font color="blue">additional</font> products, we may     not meet <font color="blue">expectations</font> for our <font color="blue">future performance</font> and our <font color="blue">stock price could</font>     decline</td>
    </tr>
    <tr>
      <td>Other  companies,  including some <font color="blue">with substantially greater</font>     financial, marketing and <font color="blue">sales resources</font>, are <font color="blue">competing with us</font> to acquire     or <font color="blue">license products</font> or <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We may not be able to acquire or     <font color="blue">license rights</font> to <font color="blue">additional</font> products or <font color="blue">product <font color="blue">candidates</font></font> on acceptable     terms, if at all</td>
    </tr>
    <tr>
      <td>Furthermore, we may not be able to <font color="blue">successfully</font> develop     any <font color="blue">product <font color="blue">candidates</font></font> we acquire or license</td>
    </tr>
    <tr>
      <td>In addition, we may acquire or     license new products with <font color="blue">different</font> marketing strategies, <font color="blue">distribution</font>     channels  and bases of <font color="blue">competition</font> than those of our <font color="blue">current products</font></td>
    </tr>
    <tr>
      <td>Therefore,  we  may  not be able to <font color="blue">compete favorably</font> in those product     <font color="blue">categories</font></td>
    </tr>
    <tr>
      <td>We may not realize all of the anticipated benefits of our recent and future     <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">acquisition</font> strategy is subject to <font color="blue">inherent risk</font> and we <font color="blue">cannot guarantee</font>     that we will be able to complete any <font color="blue">acquisition</font>, including the ability to     identify potential partners, <font color="blue">successfully</font> negotiate economically beneficial     terms, <font color="blue">successfully</font> integrate such business, retain its <font color="blue">key employees</font> and     achieve the anticipated revenue, cost benefits or synergies</td>
    </tr>
    <tr>
      <td>We review the records of companies we plan to acquire, however, even an     in-depth review of <font color="blue">records may</font> not reveal existing or <font color="blue">potential problems</font> or     <font color="blue">permit us</font> to <font color="blue">become familiar enough with</font> a business to <font color="blue">assess fully</font> its     <font color="blue">capabilities</font> and <font color="blue">deficiencies</font></td>
    </tr>
    <tr>
      <td>As a result, we may assume <font color="blue">unanticipated</font>     <font color="blue">liabilities</font>, or an <font color="blue">acquisition</font> may not perform as well as expected</td>
    </tr>
    <tr>
      <td>We also     face  the  risk  that the returns on <font color="blue"><font color="blue">acquisition</font>s</font> will not support the     <font color="blue"><font color="blue">expenditure</font>s</font> or <font color="blue">indebtedness incurred</font> to acquire <font color="blue">such businesses</font>, or the     capital <font color="blue"><font color="blue">expenditure</font>s</font> needed to develop <font color="blue">such businesses</font></td>
    </tr>
    <tr>
      <td>On October 3, 2005, we closed the <font color="blue">acquisition</font> <font color="blue">of Guilford </font>Pharmaceuticals     Inc</td>
    </tr>
    <tr>
      <td>The  <font color="blue">integration</font>  of  <font color="blue">in<font color="blue">dependent</font></font>  companies  is a complex, costly and     time-consuming process</td>
    </tr>
    <tr>
      <td>The <font color="blue">difficult</font>ies of combining the <font color="blue">operations</font> of the     companies include, <font color="blue">among others</font>:       •   <font color="blue">Retaining </font><font color="blue">key employees</font> and <font color="blue">collaborators</font>;         •   <font color="blue">Coordinating </font>research and <font color="blue">development</font> <font color="blue">activities</font>;         •   <font color="blue">Consolidating </font>corporate and <font color="blue"><font color="blue">administrative</font> functions</font>;         •   <font color="blue">Minimizing </font>the diversion of <font color="blue">management</font>’s attention from ongoing     business concerns; and         •   <font color="blue">Coordinating </font>geographically separate <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>In addition, even if we are able to <font color="blue">successfully</font> integrate the companies we     acquire, the <font color="blue">integration</font>s may not result in the <font color="blue">realization</font> of the full     benefits of <font color="blue">development</font> and <font color="blue">growth opportunities</font> that we currently expect or     that these <font color="blue">benefits will</font> be achieved within the anticipated time frame</td>
    </tr>
    <tr>
      <td>In     an <font color="blue">acquisition</font>, some customers may seek <font color="blue">alternative</font> sources of product after     the <font color="blue">announcement</font> of the merger or after the <font color="blue">merger due</font> to, among other     reasons, a desire not to do business with the <font color="blue">combined company</font> or perceived     concerns that the <font color="blue">combined company</font> may not continue to support and develop     certain  products</td>
    </tr>
    <tr>
      <td>After an <font color="blue">acquisition</font>, a <font color="blue">combined company</font> could also     experience some customer attrition or disputes by reason of the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Our failure to achieve expected <font color="blue">benefits from</font> an <font color="blue">acquisition</font> or to minimize     the impact of any negative effect could have a material adverse effect on     our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may need to obtain <font color="blue">additional</font> capital to grow our business and complete     our product portfolio <font color="blue">development</font> and expansion plans</td>
    </tr>
    <tr>
      <td>Issuance of new     securities may dilute the interests of our <font color="blue">stockholders</font> and constrain our     operating <font color="blue">flexibility</font></td>
    </tr>
    <tr>
      <td>We may need to raise <font color="blue">additional</font> funds for <font color="blue">various reasons</font> including the     following:       •   to expand our portfolio of marketed products, <font color="blue">product <font color="blue">candidates</font></font>, and     research programs;         •   to develop products we have discovered, acquired, or licensed;          •   to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>, including research and     <font color="blue">clinical trial expenses</font>;         •   to obtain <font color="blue">necessary</font> working capital; and         •   to fund operating losses</td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________           <font color="blue">Adequate </font>funds for these <font color="blue">purposes may</font> not be available when needed or on     terms acceptable to us</td>
    </tr>
    <tr>
      <td><font color="blue">Insufficient </font>funds may cause us to delay, scale     back,  or abandon some or all of our product <font color="blue">acquisition</font> and licensing     programs and product <font color="blue"><font color="blue">development</font> programs</font></td>
    </tr>
    <tr>
      <td>We may seek <font color="blue">additional</font> funding     <font color="blue">through public</font> and <font color="blue">private financing</font>, including equity and <font color="blue">debt financing</font> or     <font color="blue">enter <font color="blue">into collaborative <font color="blue">arrangements</font></font></font></td>
    </tr>
    <tr>
      <td>Any sale of <font color="blue">additional</font> convertible     <font color="blue">debt securities</font> or <font color="blue">equity securities may</font> result in <font color="blue">additional</font> dilution to     our <font color="blue">stockholders</font> and any <font color="blue">debt financing</font> may require us to pledge our assets     and <font color="blue">enter into restrictive covenants</font></td>
    </tr>
    <tr>
      <td>Entry <font color="blue">into collaborative <font color="blue">arrangements</font></font>     may  require  us  to <font color="blue">give up rights</font> to some of our products or to some     <font color="blue">potential market</font>s or to <font color="blue">enter into licensing <font color="blue">arrangements</font> on unfavorable</font>     terms</td>
    </tr>
    <tr>
      <td>If we are unable to maintain <font color="blue"><font color="blue">relationship</font>s</font> with strategic <font color="blue">collaborators</font> or     <font color="blue">enter into new</font> <font color="blue"><font color="blue">relationship</font>s</font>, we may not be able to develop any of our     <font color="blue">product <font color="blue">candidates</font></font> or <font color="blue">commercialize</font> our products in a <font color="blue">timely manner</font>, if at     all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">continued success will depend</font> in large part upon the efforts of third     parties</td>
    </tr>
    <tr>
      <td>For the research, <font color="blue">development</font>, <font color="blue">manufacture</font> and <font color="blue">commercialization</font> of     our products, we currently have, and <font color="blue">will likely</font> continue to enter into,     various <font color="blue">arrangements</font> with other <font color="blue">corporations</font>, <font color="blue">licensors</font>, licensees, outside     <font color="blue">researchers</font>, <font color="blue">consultants</font> and others</td>
    </tr>
    <tr>
      <td>However, we cannot be certain of the     actions these <font color="blue">parties will</font> take, and there is a risk that:       •   we will be unable to negotiate acceptable collaborative <font color="blue">arrangements</font>     to develop or <font color="blue">commercialize</font> our products;         •   any <font color="blue">arrangements</font> with third-<font color="blue">parties will</font> not be successful;         •   strategic <font color="blue">collaborators</font> will not fulfill their <font color="blue"><font color="blue">obligation</font>s</font> to us under     any <font color="blue">arrangements</font> entered into with them;          •    strategic <font color="blue">collaborators</font>, including Helsinn Healthcare SA, will     terminate their <font color="blue"><font color="blue">relationship</font> with</font> us; or         •   current or potential <font color="blue">collaborators</font> will pursue <font color="blue">treatments</font> for other     diseases or seek <font color="blue">alternative</font> means of developing <font color="blue">treatments</font> for the diseases     <font color="blue">targeted by</font> our programs or products</td>
    </tr>
    <tr>
      <td>Our strategic <font color="blue">collaborators</font> include public research institutions, research     <font color="blue">organizations</font>, teaching and research hospitals, community-based clinics,     testing <font color="blue">laboratories</font>, contract product formulation <font color="blue">organizations</font>, contract     packaging and <font color="blue">distribution</font> companies, <font color="blue"><font color="blue">manufacture</font>r</font>s, suppliers and license     <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>We consider our <font color="blue">arrangements</font> with Helsinn Healthcare SA,     Patheon Inc, Merck KGaA, and SuperGen, Inc</td>
    </tr>
    <tr>
      <td>to be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>If any of     our <font color="blue">collaborators</font> breaches or terminates its <font color="blue">agreement</font> with us, or otherwise     fails to conduct its <font color="blue">collaborative <font color="blue">activities</font></font> in a <font color="blue">timely manner</font>, we may     experience <font color="blue">significant</font> delays in the <font color="blue">development</font> or <font color="blue">commercialization</font> of the     products  or <font color="blue">product <font color="blue">candidates</font></font> or the <font color="blue">research program covered by</font> the     <font color="blue">agreement</font> and we may need to devote <font color="blue">additional</font> funds or other resources to     these  <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If  we are unable to <font color="blue">enter into new</font> or <font color="blue">alternative</font>     <font color="blue">arrangements</font> to continue research and <font color="blue">development</font> <font color="blue">activities</font>, or are unable     to  continue these <font color="blue">activities</font> on our own, we may have to terminate the     <font color="blue">development</font> program</td>
    </tr>
    <tr>
      <td>We have licensed the right to promote, sell and distribute Aloxi products in     the <font color="blue"><font color="blue">United States</font> </font>and Canada from <font color="blue">Helsinn Healthcare SA </font>We are <font color="blue">particularly</font>     <font color="blue"><font color="blue">dependent</font> on</font> Helsinn for our ability to <font color="blue">commercialize</font> Aloxi products</td>
    </tr>
    <tr>
      <td>We have entered a license <font color="blue">agreement</font> with <font color="blue">Helsinn Healthcare SA </font>under which     we have acquired a license to sell and distribute Aloxi products in the     <font color="blue"><font color="blue">United States</font> </font>and Canada through <font color="blue">December </font>31, 2015</td>
    </tr>
    <tr>
      <td>Furthermore, under the     terms of our license, we are required to purchase all of our Aloxi products     from  Helsinn  Birex Pharmaceutical, Ltd</td>
    </tr>
    <tr>
      <td>The license <font color="blue">agreement</font> may be     terminated  for  <font color="blue">specified reasons</font>, including if the other party is in     substantial or <font color="blue">persistent breach</font> of the <font color="blue">agreement</font>, if we have experienced a     change of control and the acquiring entity has <font color="blue">competing products</font> or our     marketing and sales related <font color="blue">commitments</font> to the licensor are not maintained     by  the  acquiring entity, or if <font color="blue">either party</font> has declared <font color="blue">bankruptcy</font></td>
    </tr>
    <tr>
      <td>Although we are not currently in breach of the license, and we believe that     <font color="blue">Helsinn Healthcare SA </font>is not currently in breach of the license, there is a     risk that <font color="blue">either party</font> could breach the license in the future</td>
    </tr>
    <tr>
      <td>In addition,     if we were to breach the supply <font color="blue">agreement</font> with Helsinn Birex Pharmaceutical     Ltd</td>
    </tr>
    <tr>
      <td>contemplated by the license, <font color="blue">Helsinn Healthcare SA </font>would be permitted     to terminate the license</td>
    </tr>
    <tr>
      <td>If the license <font color="blue">agreement</font> were terminated, we would lose all of our rights to     sell  and  distribute  Aloxi  products,  as well as all of the related     <font color="blue">intellectual property</font> and all <font color="blue"><font color="blue">regulatory</font> approvals</font></td>
    </tr>
    <tr>
      <td>In addition, Helsinn     Healthcare SA holds the rights to <font color="blue">palonosetron</font> (the active ingredient in     Aloxi  products) through an <font color="blue">agreement</font> with Syntex (USA) Inc</td>
    </tr>
    <tr>
      <td>and F     Hoffmann-La Roche AG We cannot be certain of the actions that these parties     will take, and there is a risk that these third <font color="blue">parties will</font> end their     <font color="blue">relationship</font>  with  us,  which  would  leave  <font color="blue">us without rights</font> to the     <font color="blue">pharmaceutical</font> preparations, products and know-how required to produce <font color="blue">Aloxi     </font>products</td>
    </tr>
    <tr>
      <td>As a consequence of such a <font color="blue">termination</font>, we would lose all of our     rights to sell and distribute Aloxi products, which would harm our business     and could cause our stock price to decline <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>30       _________________________________________________________________           We <font color="blue">rely on <font color="blue">multinational</font></font> and <font color="blue">foreign <font color="blue"><font color="blue">pharmaceutical</font> companies</font></font> to develop and     <font color="blue">commercialize</font> our products and <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue">markets outside</font> the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>With respect to products in which we own <font color="blue">rights outside</font> the <font color="blue">United States</font>,     we  have <font color="blue">entered into alliances with various <font color="blue">multinational</font></font> and foreign     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> related to the <font color="blue">development</font> and <font color="blue">commercialization</font> of     our products and <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue">markets outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our continued <font color="blue"><font color="blue">relationship</font>s</font> with strategic <font color="blue">collaborators</font> are <font color="blue">dependent</font> in     part on the <font color="blue">successful <font color="blue">achievement</font></font> of <font color="blue">development</font> <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td>If we or our     <font color="blue">collaborators</font> do not achieve these <font color="blue">milestones</font>, or we are unable to enter     into  <font color="blue">agreement</font>s  with  our <font color="blue">collaborators</font> to modify their terms, these     <font color="blue">agreement</font>s could terminate, <font color="blue">which could</font> cause a loss of <font color="blue">licensing revenue</font>, a     loss of <font color="blue">future commercial product potential</font> and a decline in our stock     price</td>
    </tr>
    <tr>
      <td>We recognize <font color="blue">licensing revenue</font> from our strategic <font color="blue">collaborators</font> as a portion     of our <font color="blue">total revenue</font></td>
    </tr>
    <tr>
      <td>Future licensing <font color="blue">revenues from</font> these <font color="blue">collaborators</font>     <font color="blue">will likely</font> fluctuate from quarter-to-quarter and year-to-year depending on:       •   the <font color="blue">achievement</font> of <font color="blue">milestones</font> by us or our <font color="blue">collaborators</font>;         •   the amount of <font color="blue">product sales</font> and royalty-generating <font color="blue">activities</font>;         •   the timing of initiating <font color="blue">additional</font> licensing <font color="blue"><font color="blue">relationship</font>s</font>; and         •   our <font color="blue">continuing <font color="blue">obligation</font></font> related to <font color="blue">license payments</font></td>
    </tr>
    <tr>
      <td>If  we  fail to compete <font color="blue">successfully</font> with our <font color="blue"><font color="blue">competitor</font>s</font>, our product     <font color="blue">revenues could decrease</font> and our <font color="blue"><font color="blue">stock price could</font> decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition  </font>in  the  <font color="blue">pharmaceutical</font>  industry is intense</td>
    </tr>
    <tr>
      <td>Most of our     <font color="blue"><font color="blue">competitor</font>s</font> are large, <font color="blue">multinational</font> <font color="blue"><font color="blue">pharmaceutical</font> companies</font> that have     <font color="blue">considerably</font> greater financial, sales, marketing and technical resources     than  we  do</td>
    </tr>
    <tr>
      <td>Most of our present and potential <font color="blue"><font color="blue">competitor</font>s</font> also have     dedicated research and <font color="blue">development</font> <font color="blue">capabilities</font> that may allow them to     develop new or improved products that <font color="blue">compete with</font> our products</td>
    </tr>
    <tr>
      <td>Currently,     Aloxi  competes  with  three  other <font color="blue">products from</font> the 5-HT[3] receptor     <font color="blue">antagonist</font> class of compounds, as well as <font color="blue">products from</font> other chemical     classes that are also used for the prevention of <font color="blue">chemotherapy</font>-induced nausea     and  vomiting</td>
    </tr>
    <tr>
      <td>These products are <font color="blue">marketed by</font> GlaxoSmithKline, Roche,     Sanofi-Aventis, Merck and other large <font color="blue">multinational</font> <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">Aloxi     </font>does not compete <font color="blue">successfully</font> with <font color="blue">existing product</font>s on the market, our     <font color="blue"><font color="blue">stock price could</font> decline</font> <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Gliadel <font color="blue">currently competes as</font> a     treatment  of malignant glioma with traditional systemic <font color="blue">chemotherapy</font>,     radioactive seeds, radiation catheters, TEMODAR Capsules, a <font color="blue">chemotherapy</font>     product  <font color="blue">manufacture</font>d  by Schering Corporation, and other <font color="blue">experimental</font>     protocols</td>
    </tr>
    <tr>
      <td>Additionally, MedImmune, Inc, Daichi Pharmaceutical, and three     US generic <font color="blue"><font color="blue">manufacture</font>r</font>s have drugs that are approved for sale and compete     in the <font color="blue">same markets as</font> Salagen</td>
    </tr>
    <tr>
      <td>Other <font color="blue"><font color="blue">pharmaceutical</font> companies</font> are developing products, which, if approved     by the FDA, <font color="blue">will compete directly with</font> our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> could     also develop and <font color="blue">introduce generic drugs comparable</font> to our products, or     drugs or <font color="blue">combination</font> of drugs or other therapies that address the underlying     causes of the symptoms that our <font color="blue">products treat</font></td>
    </tr>
    <tr>
      <td>If a product developed by a     <font color="blue">competitor</font> is more <font color="blue">effective</font> than our product, or priced lower than our     product,  our <font color="blue">product revenue</font> could decrease and our <font color="blue">stock price could</font>     decline</td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">dependent</font> on</font> our <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>If we are not able to attract and     retain <font color="blue">key employees</font> and <font color="blue">consultants</font>, our product <font color="blue">development</font>, marketing and     <font color="blue">commercialization</font> plans could be harmed</td>
    </tr>
    <tr>
      <td>We are highly <font color="blue"><font color="blue">dependent</font> on</font> the members of our scientific, commercial and     <font color="blue"><font color="blue">management</font> staff</font></td>
    </tr>
    <tr>
      <td>If we are not able to retain any of these persons, our     product <font color="blue">development</font>, marketing and <font color="blue">commercialization</font> plans may suffer and     our  stock  <font color="blue">price could decline</font></td>
    </tr>
    <tr>
      <td>None of our executive officers has an     <font color="blue">employment</font> <font color="blue">agreement</font> with us</td>
    </tr>
    <tr>
      <td>If we are unable to retain our scientific,     commercial and <font color="blue"><font color="blue">management</font> staff</font>, we will need to hire <font color="blue">additional</font> qualified     personnel for us to pursue our product <font color="blue">acquisition</font>, <font color="blue">development</font>, marketing     and <font color="blue">commercialization</font> plans</td>
    </tr>
    <tr>
      <td>We may not be able to attract and retain <font color="blue">personnel on</font> acceptable terms,     given the <font color="blue">competition</font> for such personnel among bio<font color="blue">technology</font>, <font color="blue">pharmaceutical</font>     and healthcare companies, universities and non-profit research institutions</td>
    </tr>
    <tr>
      <td>If we are not able to attract and retain <font color="blue">qualified personnel</font>, our product     <font color="blue">acquisition</font>, <font color="blue">development</font>, marketing and <font color="blue">commercialization</font> plans will suffer     and our <font color="blue"><font color="blue">stock price could</font> decline</font></td>
    </tr>
    <tr>
      <td>If  we  are  unable to keep <font color="blue">up with rapid <font color="blue">technological</font></font> changes in the     <font color="blue">pharmaceutical</font> or <font color="blue">bio<font color="blue">technology</font> industries</font>, we may be unable to continue our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> industries</font> have experienced rapid and     <font color="blue">significant</font> <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">pharmaceutical</font> <font color="blue">technology</font>     and <font color="blue">bio<font color="blue">technology</font> will continue</font> to develop rapidly</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will</font>     depend, in large part, on our ability to develop and maintain <font color="blue">technology</font>     that is <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>If other companies achieve <font color="blue">technological</font> advances with     their products or obtain FDA approval before we are able to obtain such     approval, our <font color="blue">products may become obsolete</font> before they are marketed or     before we recover any of our <font color="blue">development</font> and <font color="blue">commercialization</font> expenses     <font color="blue">incurred with respect</font> to <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">alternative</font> therapies     or new medical <font color="blue">treatments</font> could alter existing treatment regimens, and     <font color="blue">thereby reduce</font> the need for one or more of our products, <font color="blue">which could</font> result     in  the  <font color="blue">termination</font>  of the <font color="blue">development</font> in one or more of our product     <font color="blue">candidates</font>, or in the decline in sales of one of our <font color="blue">approved product</font>s,     <font color="blue">which could</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________           If we do not receive <font color="blue"><font color="blue">regulatory</font> approvals</font> for our <font color="blue">product <font color="blue">candidates</font></font>, or if     <font color="blue">regulatory</font>  approval  is  delayed for any reason, we will be unable to     <font color="blue">commercialize</font> and sell our <font color="blue">products as</font> we expect</td>
    </tr>
    <tr>
      <td>Prior to marketing, each of our <font color="blue">product <font color="blue">candidates</font></font> must undergo an extensive     <font color="blue">regulatory</font> approval process conducted by the FDA <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and by     comparable agencies in other countries</td>
    </tr>
    <tr>
      <td>The product <font color="blue">development</font> and approval     process can take many years and require the <font color="blue">expenditure</font> of substantial     resources</td>
    </tr>
    <tr>
      <td>There is risk that the FDA or a foreign <font color="blue">regulatory</font> authority will     not  approve  in  a  <font color="blue">timely manner</font>, if at all, any product we develop</td>
    </tr>
    <tr>
      <td>Generally, the FDA approves for sale only a very small percentage of newly     discovered <font color="blue">pharmaceutical</font> compounds that enter preclinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">may encounter delays</font> or denials in <font color="blue"><font color="blue">regulatory</font> approvals</font> due to changes in     FDA <font color="blue">policy during</font> the period of <font color="blue">development</font>, or changes in the <font color="blue">requirements</font>     for <font color="blue">regulatory</font> review of each submitted new drug <font color="blue">application</font> (“NDA”)</td>
    </tr>
    <tr>
      <td>There is also risk that <font color="blue">regulatory</font> <font color="blue">authorities</font> <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and     elsewhere may not allow us to conduct planned <font color="blue">additional</font> clinical testing of     any  of our <font color="blue">product <font color="blue">candidates</font></font>, including irofulven, Dacogen, Saforis,     <font color="blue">amolimogene</font> (HPV E6 E7 plasmid), ZYC300, Aquavan or Aloxi products, or that,     if permitted, this <font color="blue">additional</font> clinical testing will not prove that these     <font color="blue">product <font color="blue">candidates</font></font> are safe and <font color="blue">effective</font> to the extent <font color="blue">necessary</font> to permit     us to obtain marketing approvals from <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Once we receive <font color="blue">regulatory</font> approval to market a product, our promotional     <font color="blue">activities</font> are subject to extensive <font color="blue">regulation from</font> the FDA, the <font color="blue">Federal     </font>Trade Commission (“FTC”), the Office of the Inspector General of the US     Department of Health and Human Services (“OIG”), or State Attorney General</td>
    </tr>
    <tr>
      <td>If we violate any <font color="blue">such <font color="blue">regulations</font></font> it could be damaging to our reputation     and restrict our ability to sell or market our products, and our business     <font color="blue">condition could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>In  their  regulation of <font color="blue">advertising</font>, the FDA from time to time issues     <font color="blue">correspondence</font> alleging that some <font color="blue">advertising</font> or <font color="blue">promotional practices</font> are     false, misleading or <font color="blue">deceptive</font></td>
    </tr>
    <tr>
      <td>The FDA has the power to impose a <font color="blue">wide array</font>     of <font color="blue">sanctions on</font> companies for such <font color="blue">advertising</font> or <font color="blue">promotional practices</font>, and     the receipt of <font color="blue">correspondence</font> from the FDA alleging these <font color="blue">practices could</font>     result in any or all of the following:       •   incurring substantial expenses, including fines, penalties, legal fees     and costs to <font color="blue">comply with</font> the FDA’s <font color="blue">requirements</font>;         •   changes in the methods of marketing and <font color="blue">selling products</font>;         •   taking FDA-mandated corrective action, which may include placing     <font color="blue">advertisements</font>  or  <font color="blue">sending letters</font> to physicians, rescinding previous     <font color="blue">advertisements</font> or promotions; and         •   <font color="blue">disruption</font> in the <font color="blue">distribution</font> of products and loss of <font color="blue">revenue until</font>     <font color="blue">compliance with</font> the FDA’s position is obtained</td>
    </tr>
    <tr>
      <td>If we were to become subject to any of the above <font color="blue">requirements</font>, it could be     damaging to our reputation, and our business <font color="blue">condition could</font> be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>may prescribe <font color="blue"><font color="blue">pharmaceutical</font> products</font> for uses that are not     described in a product’s labeling or <font color="blue">differ from</font> those <font color="blue">tested by us</font> and     <font color="blue">approved by</font> the FDA While such “off-label” uses are common and the FDA does     not regulate physicians’ choice of <font color="blue">treatments</font>, the FDA does restrict a     <font color="blue"><font color="blue">manufacture</font>r</font>’s communications on the subject of off-label use</td>
    </tr>
    <tr>
      <td><font color="blue">Companies     </font><font color="blue">cannot actively promote</font> FDA-approved <font color="blue"><font color="blue">pharmaceutical</font> products</font> for off-label     uses, but under certain limited <font color="blue">circumstances</font> they <font color="blue">may disseminate articles</font>     to  <font color="blue">physicians published</font> in peer-reviewed journals</td>
    </tr>
    <tr>
      <td>If our promotional     <font color="blue">activities</font>  of  this type fail to <font color="blue">comply with</font> the FDA’s <font color="blue">regulations</font> or     <font color="blue">guidelines</font>, we may be subject to <font color="blue">warnings from</font>, or <font color="blue">enforcement action by</font>,     the FDA     Additionally, if we fail to <font color="blue">comply with</font> the FDA <font color="blue">regulations</font> prohibiting     promotion of off-label uses and the promotion of our products, the FDA, FTC,     Department of Justice, OIG or State Attorney General <font color="blue">could bring enforcement</font>     <font color="blue">actions against us</font> that <font color="blue">would inhibit</font> our marketing <font color="blue">capabilities</font> as well as     result in <font color="blue">significant</font> penalties</td>
    </tr>
    <tr>
      <td>If we are unable to obtain <font color="blue">intellectual property</font> protection, or protect our     <font color="blue">proprietary</font> <font color="blue">technology</font>, we may be unable to compete <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>We hold an <font color="blue">exclusive license</font> <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and Canada on patents     covering Aloxi</td>
    </tr>
    <tr>
      <td>In addition, we hold an exclusive, worldwide license on     patents and patent <font color="blue">application</font>s covering acylfulvene <font color="blue"><font color="blue">proprietary</font> rights</font>,     including irofulven</td>
    </tr>
    <tr>
      <td>The <font color="blue">license applicable</font> to these <font color="blue">technologies</font> is subject     to <font color="blue">certain statutory rights</font> held by the US <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>Even though we have     licensed these patents, we may not have <font color="blue">exclusive rights</font> to all possible     <font color="blue">acylfulvene analogs</font>, all <font color="blue">possible methods</font> of using <font color="blue">acylfulvene analogs</font> to     <font color="blue">treat tumors</font> or all <font color="blue">possible synthetic methods</font> for preparing <font color="blue">acylfulvenes</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">licensed rights</font> to patents and patent <font color="blue">application</font>s covering     MG98</td>
    </tr>
    <tr>
      <td><font color="blue">Protection </font>of these rights and creation of <font color="blue">additional</font> rights involve     joint <font color="blue">responsibilities</font> between us and the <font color="blue">respective license party</font></td>
    </tr>
    <tr>
      <td>We have     recently  acquired  rights to patents and patent <font color="blue">application</font>s covering     <font color="blue">technologies</font> that were owned by or licensed to Zycos, Inc, and Aesgen,     Inc, and those rights that were licensed <font color="blue">from <font color="blue">third parties</font></font> were assigned     to us in those <font color="blue"><font color="blue">transaction</font>s</font></td>
    </tr>
    <tr>
      <td>We have                                         32       _________________________________________________________________           <font color="blue">also recently</font> obtained a worldwide, <font color="blue">exclusive license</font> of <font color="blue">certain rights</font> to     patents and patent <font color="blue">application</font>s covering <font color="blue">technologies</font> that are owned by     SuperGen, Inc, or licensed to SuperGen, Inc, <font color="blue">from <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>In  our  <font color="blue">acquisition</font>  of Guilford, we obtained an <font color="blue">exclusive license</font> to     <font color="blue">intellectual property</font>, including patents, patent <font color="blue">application</font>s and know-how,     related to Gliadel, which requires us to pay a royalty to the Massachusetts     Institute of Technology <font color="blue">on revenue from</font> Gliadel</td>
    </tr>
    <tr>
      <td>Our US <font color="blue">patent protection</font>     for Gliadel expires in August 2006</td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">February </font>2003, the FDA     <font color="blue">awarded orphan drug status</font> for Gliadel for seven years for the treatment of     patients  with malignant glioma undergoing primary surgical resection</td>
    </tr>
    <tr>
      <td>Accordingly, following the expiration of US <font color="blue">patent protection</font>, we now have     approximately four <font color="blue">additional</font> years of <font color="blue">market exclusivity</font> for Gliadel for     initial surgical resection</td>
    </tr>
    <tr>
      <td>However, there can be no assurance that others     will not enter the <font color="blue">market with</font> a <font color="blue">generic copy</font> of Gliadel for recurrent     surgical resection</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of such a <font color="blue">generic copy</font> could <font color="blue">negatively</font>     impact  our <font color="blue">revenues from</font> Gliadel for initial surgical resection after     August 2006</td>
    </tr>
    <tr>
      <td>Our pending patent <font color="blue">application</font>s, those we may file in the future, or those     we license <font color="blue">from <font color="blue">third parties</font></font>, may not result in patents being issued</td>
    </tr>
    <tr>
      <td>Patents, if issued, may be challenged, invalidated or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>In     addition, other <font color="blue">entities may</font> develop similar <font color="blue">technologies</font> that <font color="blue">fall outside</font>     the scope of our patents</td>
    </tr>
    <tr>
      <td>Thus, any patent rights that we own or license     <font color="blue">from <font color="blue">third parties</font></font> may not provide sufficient protection against potential     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>In  the  event  that our <font color="blue">technologies</font> or methods used in the course of     developing or selling our <font color="blue">products infringe</font> the patents or violate other     <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font>, we and our strategic <font color="blue">collaborators</font> may     be prevented from pursuing product <font color="blue">development</font> or <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In addition to patents, we <font color="blue">rely on trade secrets</font> and <font color="blue">proprietary</font> know-how</td>
    </tr>
    <tr>
      <td>We  protect  our  <font color="blue">proprietary</font>  <font color="blue">technology</font>  and  processes  in  part by     <font color="blue">confidentiality</font>  <font color="blue">agreement</font>s  with  our  <font color="blue">collaborators</font>,  employees  and     <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>There is a risk that:       •   these <font color="blue">confidentiality</font> <font color="blue">agreement</font>s will be breached;         •   we will not have <font color="blue">adequate remedies</font> for any breach of these <font color="blue">agreement</font>s;         •   our <font color="blue">trade secrets will</font> otherwise become known; or         •   our <font color="blue">trade secrets will</font> be <font color="blue">in<font color="blue">dependent</font></font>ly discovered and used by     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>The bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font> industries have been <font color="blue">characterize</font>d by     <font color="blue">litigation</font> regarding patents and other <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>If we     become involved in any <font color="blue">litigation</font>, interference or other <font color="blue">administrative</font>     <font color="blue">proceedings</font>,  we will incur substantial expense and the efforts of our     technical  and  <font color="blue">management</font>  personnel  will  be  diverted</td>
    </tr>
    <tr>
      <td>An adverse     de<font color="blue">termination</font> may subject us to <font color="blue">significant</font> <font color="blue">liabilities</font> or require us to     cease using the <font color="blue">technology</font> or to <font color="blue">seek licenses</font> that may not be available     <font color="blue">from <font color="blue">third parties</font></font> on <font color="blue">commercially</font> favorable terms, if at all, or to cease     <font color="blue">manufacturing</font> and selling our products</td>
    </tr>
    <tr>
      <td>This could cause us to terminate the     <font color="blue">development</font>  of  one or more of our <font color="blue">product <font color="blue">candidates</font></font>, to <font color="blue">discontinue</font>     marketing an <font color="blue">existing product</font>, or to <font color="blue">pay royalties</font> to a <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>If  the use of one of our products is alleged to be harmful, we may be     subject to costly and damaging product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>We <font color="blue">face exposure</font> to product <font color="blue">liability</font> claims in the event that the use of     any of our products is alleged to have harmed someone</td>
    </tr>
    <tr>
      <td>Although we have     taken, and continue to take, what we believe are <font color="blue">appropriate precautions</font>,     there  is a risk that we will not be able to avoid <font color="blue">significant</font> product     <font color="blue">liability</font> exposure</td>
    </tr>
    <tr>
      <td>We currently have product <font color="blue">liability</font> insurance in the     amount of dlra30 million per occurrence and in the aggregate for the year for     products, <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>There is a risk that our     <font color="blue">insurance will</font> not be sufficient to cover claims</td>
    </tr>
    <tr>
      <td>There is also a risk that     adequate  insurance  coverage  will  not be available in the future on     <font color="blue">commercially</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>The <font color="blue">successful assertion</font> of an     uninsured product <font color="blue">liability</font> or other claim <font color="blue">against us could</font> cause us to     incur a <font color="blue">significant</font> expense to pay such a claim, could <font color="blue">adversely</font> affect our     product <font color="blue">development</font> and could cause a decline in our <font color="blue">product revenue</font> and the     price of our stock</td>
    </tr>
    <tr>
      <td>In  addition  to  product <font color="blue">liability</font> risks associated with sales of our     products, we may be liable to the claims of <font color="blue">individuals</font> who <font color="blue">participate</font> in     <font color="blue">clinical trials</font> of our products</td>
    </tr>
    <tr>
      <td>A number of patients who <font color="blue">participate</font> in     trials are <font color="blue">already critically ill</font> when they enter a trial</td>
    </tr>
    <tr>
      <td>The waivers we     obtain may not be enforceable and may not protect us from <font color="blue">liability</font> or the     costs of product <font color="blue">liability</font> <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">liability</font> insurance may     not provide adequate protection against potential <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Moreover, we     may not be able to maintain our <font color="blue">insurance on</font> acceptable terms</td>
    </tr>
    <tr>
      <td>As a result     of these factors, a product <font color="blue">liability</font> claim, even if <font color="blue">successfully</font> defended,     could cause us to incur a <font color="blue">significant</font> expense to defend such a claim, could     <font color="blue">adversely</font> affect our product <font color="blue">development</font> and could cause a decline in our     <font color="blue">product revenue</font> and the price of our stock</td>
    </tr>
    <tr>
      <td>33       _________________________________________________________________           We could become the subject of legal <font color="blue">proceedings</font> or <font color="blue">investigations</font> that     could result in substantial fines, penalties, injunctive or <font color="blue">administrative</font>     penalties  and criminal charges, which would increase our expenses and     redirect <font color="blue">management</font>’s attention away from business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">operations</font> are subject to a wide range of laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue"><font color="blue">pharmaceutical</font> companies</font> have been the subjects of legal <font color="blue">proceedings</font>     or <font color="blue">investigations</font> related to pricing, marketing, promotional and clinical     trial  practices</td>
    </tr>
    <tr>
      <td>If  we  become  the subject of legal <font color="blue">proceedings</font> or     <font color="blue">investigations</font>, our <font color="blue">expenses would increase</font> and <font color="blue">commercialization</font> of our     <font color="blue">products could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">management</font>’s attention would     be <font color="blue">diverted from</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we issue a <font color="blue">product recall</font>, we may not sell as much of our products in the     future and we may incur <font color="blue">significant</font> expenses</td>
    </tr>
    <tr>
      <td>The  FDA or other <font color="blue">government</font> agencies having <font color="blue">regulatory</font> authority over     <font color="blue">product sales</font> may request <font color="blue"><font color="blue">product recall</font>s</font> or we may <font color="blue">in<font color="blue">dependent</font></font>ly issue     product  recalls</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">product recall</font>s</font> may occur due to <font color="blue">manufacturing</font>     issues, safety concerns or other reasons</td>
    </tr>
    <tr>
      <td>We do not carry any insurance to     cover the risk of a <font color="blue">product recall</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">product recall</font> could have a material     adverse effect on our <font color="blue">product revenue</font> and could cause the price of our stock     to decline</td>
    </tr>
    <tr>
      <td>If  we  or  patients  using our products are unable to obtain adequate     <font color="blue">reimbursement</font> from <font color="blue">government</font> health administration <font color="blue">authorities</font>, private     <font color="blue">health insurers</font> and other <font color="blue">organizations</font>, our <font color="blue">product sales</font>, net income, cash     balances and price of our <font color="blue">stock could decline</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our products <font color="blue">successfully</font> will depend in part     on the extent to which private <font color="blue">health insurers</font>, <font color="blue">organizations</font> such as HMOs     and <font color="blue">government</font>al <font color="blue">authorities</font> reimburse the cost of our products and related     <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>Third-party payors are <font color="blue"><font color="blue">increasingly</font> <font color="blue">challenging</font></font> the prices     charged for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>Also, the trend toward managed     health care <font color="blue">in the <font color="blue"><font color="blue">United States</font> </font></font>and the <font color="blue">concurrent growth</font> of <font color="blue">organizations</font>     such as HMOs, <font color="blue">which could</font> control or <font color="blue">significant</font>ly influence the purchase of     <font color="blue">health care services</font> and products, as well as <font color="blue">legislative</font> proposals to     <font color="blue">reform health care</font> or reduce <font color="blue">government</font> insurance programs, may all result     in <font color="blue">lower prices</font> for or rejection of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">cost containment</font>     measures that <font color="blue">health care payors</font> and providers are <font color="blue">instituting</font> and the     effect of any <font color="blue">health care reform could <font color="blue">materially</font></font> and <font color="blue">adversely</font> affect our     ability to operate profitably</td>
    </tr>
    <tr>
      <td>There is <font color="blue">uncertainty</font> about the <font color="blue"><font color="blue">reimbursement</font> status</font> of <font color="blue">healthcare products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">profitability</font> will depend</font> in part on: (1) the price we are able to     charge for our products, and (2) the <font color="blue">availability</font> of <font color="blue">adequate <font color="blue">reimbursement</font></font>     for our products to providers from third-party payors, such as <font color="blue">government</font>     entities, private <font color="blue">health insurers</font> and managed care <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Federal     </font>and  state <font color="blue">regulations</font> govern or influence the <font color="blue"><font color="blue">reimbursement</font> status</font> of     healthcare  products  in  many  situations  and third-party payors are     <font color="blue"><font color="blue">increasingly</font> <font color="blue">challenging</font></font> the pricing of <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>The Medicare Prescription Drug, Improvement, and Modernization Act of 2003     together with rulemaking by the Centers for Medicare and Medicaid Services     (“CMS”)  require  a number of changes in Medicare practices, including     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>The changes made to date are not expected to have an adverse     <font color="blue">affect on</font> our <font color="blue">operations</font>, sales or the price of our stock, but we cannot     predict the impact, if any, of future provider <font color="blue">reimbursement</font> changes</td>
    </tr>
    <tr>
      <td>Aloxi, Salagen, and Gliadel <font color="blue">generally</font> have <font color="blue">been eligible</font> for <font color="blue">reimbursement</font>     to providers from third-party payors and we have applied for, or in certain     cases  already received <font color="blue">confirmation</font> of, <font color="blue">reimbursement</font> eligibility for     providers  for  Aloxi</td>
    </tr>
    <tr>
      <td>Third-party  <font color="blue">reimbursement</font> is important to the     <font color="blue">commercialization</font>  of  our  products</td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> entities and other     third-party payors do not provide <font color="blue">adequate <font color="blue">reimbursement</font></font> levels to providers     for our products, our product and <font color="blue"><font color="blue">license revenues</font> would</font> be <font color="blue">materially</font> and     <font color="blue">adversely</font> affected and our <font color="blue"><font color="blue">stock price could</font> decline</font></td>
    </tr>
    <tr>
      <td>In recent years, various parties have proposed a number of <font color="blue">legislative</font> and     <font color="blue">regulatory</font> proposals aimed at changing <font color="blue">national healthcare systems</font></td>
    </tr>
    <tr>
      <td>In the     <font color="blue">United States</font>, we expect that <font color="blue">there will continue</font> to be a number of federal     and  state  proposals  to  implement <font color="blue">government</font> control of pricing and     <font color="blue">profitability</font> of prescription <font color="blue">pharmaceutical</font>s</td>
    </tr>
    <tr>
      <td>Cost controls, if <font color="blue">mandated by</font>     a  <font color="blue">government</font> agency, could decrease the price that we receive for our     current  or <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>These proposals, if enacted, could have a     material adverse effect on our product and <font color="blue">license revenues</font> and could cause     our stock price to decline</td>
    </tr>
    <tr>
      <td>In certain countries, <font color="blue">regulatory</font> <font color="blue">authorities</font>     <font color="blue">must also approve</font> the <font color="blue">sales price</font> of a product after they <font color="blue">grant marketing</font>     approval</td>
    </tr>
    <tr>
      <td>There is a risk that we will not be able to obtain satisfactory     prices in <font color="blue">foreign markets even</font> if we obtain <font color="blue">marketing approval from foreign</font>     <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font>, and the <font color="blue">operations</font> of our third-party <font color="blue">contractors</font>, involve     <font color="blue"><font color="blue">hazardous</font> materials</font> that <font color="blue">could expose us</font> to <font color="blue">liability</font> if <font color="blue">environmental</font>     damage occurs</td>
    </tr>
    <tr>
      <td>Our research, <font color="blue">development</font> and <font color="blue">manufacturing</font> <font color="blue">operations</font> and the <font color="blue">operations</font> of     our  third-party  <font color="blue">contractors</font>  involve the <font color="blue">controlled use</font> of <font color="blue">hazardous</font>     materials</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot eliminate</font> the risk of <font color="blue"><font color="blue">accident</font>al contamination</font> or     injury  from  these  materials</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">comply with</font> <font color="blue">environmental</font>     <font color="blue">regulations</font>, we may face <font color="blue">significant</font> fines or penalties</td>
    </tr>
    <tr>
      <td>In the event of an     <font color="blue">accident</font> or <font color="blue">environmental</font> discharge, <font color="blue">third parties</font> or <font color="blue">government</font>al entities     may hold us liable for any resulting damages, which, along with fines and     penalties,  may exceed our <font color="blue">financial resources</font> and may have a material     adverse effect on our ability to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>34       _________________________________________________________________           Our stock price is volatile, which may result in <font color="blue">significant</font> losses to     <font color="blue">stockholders</font> and holders of our convertible notes</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our convertible notes is <font color="blue">significant</font>ly impacted by the     price of our <font color="blue">common stock</font>, which has <font color="blue">historically been volatile</font></td>
    </tr>
    <tr>
      <td>There has     been <font color="blue">significant</font> <font color="blue">volatility</font> in the <font color="blue">market price</font>s of <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> companies’ securities</td>
    </tr>
    <tr>
      <td>Various factors and <font color="blue">events may</font> have a     <font color="blue">significant</font> impact on the <font color="blue">market price</font> of our <font color="blue">common stock</font>, and some of     these factors are beyond our control</td>
    </tr>
    <tr>
      <td>These factors include:       •   <font color="blue">fluctuations</font> in our operating results;         •   <font color="blue"><font color="blue">announcement</font>s</font> of <font color="blue">technological</font> innovations or <font color="blue"><font color="blue">acquisition</font>s</font> or     licensing of <font color="blue">therapeutic</font> products or <font color="blue">product <font color="blue">candidates</font></font> by us or our     <font color="blue"><font color="blue">competitor</font>s</font>;         •   published reports by <font color="blue">securities analysts</font>;         •   positive or negative progress with our <font color="blue">clinical trials</font>;         •   <font color="blue">government</font>al regulation, including healthcare <font color="blue">reimbursement</font> policies;         •   <font color="blue">development</font>s in patent or other <font color="blue"><font color="blue">proprietary</font> rights</font>;         •   <font color="blue">development</font>s in our <font color="blue"><font color="blue">relationship</font> with</font> <font color="blue">collaborators</font> and suppliers, and     <font color="blue"><font color="blue">announcement</font>s</font> of <font color="blue">new strategic collaborations</font>;         •   public concern as to the safety and efficacy of our products; and         •   <font color="blue">general market conditions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> has been, and <font color="blue">could continue</font> to be,     subject to wide <font color="blue">fluctuations</font> in response to these factors, including the     sale  or <font color="blue">attempted sale</font> of a large amount of our <font color="blue">common stock</font> into the     market</td>
    </tr>
    <tr>
      <td>Our stock price ranged from dlra3dtta43 to dlra34dtta49 per share during the     three-year period ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Broad market <font color="blue">fluctuations</font> may     also <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In the past, following large falls in the price of a company’s shares,     securities class action <font color="blue">litigation</font> has <font color="blue">often been initiated against</font> that     company</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>of this type could result in substantial costs and     diversion of <font color="blue">management</font>’s attention and resources, <font color="blue">which could</font> harm our     business</td>
    </tr>
    <tr>
      <td>Any adverse de<font color="blue">termination</font> in <font color="blue">litigation</font> could subject us to     <font color="blue">significant</font> <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>We have outstanding options, convertible notes and warrants that have the     potential to <font color="blue">dilute stockholder value</font> and cause our <font color="blue">stock value</font> to decline</td>
    </tr>
    <tr>
      <td>We <font color="blue">routinely grant stock options</font> to our employees and other <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td>At     <font color="blue">December </font>31, 2005, we had <font color="blue">options outstanding at option prices ranging from</font>     dlra1dtta81 to dlra33dtta22 for 10dtta4 million shares of our <font color="blue">common stock</font> that have been     registered for resale</td>
    </tr>
    <tr>
      <td>Additionally, in our <font color="blue">acquisition</font> of Guilford, we     assumed warrants to purchase 319cmam206 of our shares at a <font color="blue">weighted average</font>     exercise price (net of cash we would be required to <font color="blue">pay on exercise</font>) of     dlra61dtta21</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also issued convertible debt</font> that is <font color="blue">convertible into</font>     8dtta3 million shares of <font color="blue">common stock</font> at an <font color="blue">initial conversion price</font> of dlra31dtta46     per share of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conversion </font>of our convertible debt is <font color="blue">contingent</font>     on a number of factors that have not yet been satisfied</td>
    </tr>
    <tr>
      <td>Consequently, we     are  not  able to estimate when, if ever, our <font color="blue">convertible debt will</font> be     converted into <font color="blue">common stock</font>, but any <font color="blue">such conversion would almost certainly</font>     <font color="blue">dilute stockholder value</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Guilford Merger </font>resulted in an <font color="blue">obligation</font> for us to make an offer to     repurchase  all  the Guilford convertible subordinatd notes (“Guilford     Notes”)  due  July 1, 2008 in <font color="blue">accordance with</font> the terms of the related     <font color="blue">indenture at</font> a <font color="blue">repurchase price</font> in cash equal to 100prca of the principal     amount  of  the Notes, plus accrued and <font color="blue">unpaid interest</font> and liquidated     damages, if any, up to <font color="blue">but excluding</font> the <font color="blue">payment date</font></td>
    </tr>
    <tr>
      <td>Each dlra1cmam000 principal     amount of the <font color="blue">Guilford Notes </font>was convertible, at the option of the holder,     into (i) 17dtta6772 shares of <font color="blue">MGI PHARMA </font><font color="blue">common stock</font>, and (ii) dlra180dtta28 in cash     through November 28, 2005</td>
    </tr>
    <tr>
      <td>At the expiration of the offer to repurchase,     dlra1dtta5 million of the <font color="blue">Guilford Notes </font>were outstanding</td>
    </tr>
    <tr>
      <td>If some or all of such shares are sold into the <font color="blue">public market over</font> a short     time period, the value of our stock is likely to decline, as the <font color="blue">market may</font>     not be able to absorb those shares at the prevailing <font color="blue">market price</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">sales may also</font> make it more <font color="blue">difficult</font> for us to <font color="blue">sell equity securities</font> in     the <font color="blue">future on terms</font> that we deem acceptable</td>
    </tr>
    <tr>
      <td>35       _________________________________________________________________           Our <font color="blue">charter documents</font>, our <font color="blue">stockholder rights</font> plan and <font color="blue">Minnesota </font>law contain     provisions that <font color="blue">could delay</font> or prevent an <font color="blue">acquisition</font> of our company</td>
    </tr>
    <tr>
      <td>Our <font color="blue">charter documents</font> contain provisions that may discourage <font color="blue">third parties</font>     <font color="blue">from seeking</font> to acquire our company</td>
    </tr>
    <tr>
      <td>These provisions include:       •   advance notice <font color="blue">requirements</font> for <font color="blue">stockholder proposals</font> and <font color="blue">nominations</font>;     and         •   the authority of the board of <font color="blue">directors</font> to issue, without stockholder     approval, preferred stock with such terms as the board of <font color="blue">directors</font> may     determine</td>
    </tr>
    <tr>
      <td>In addition, our board of <font color="blue">directors</font> has adopted a <font color="blue">stockholder rights</font> plan,     or poison pill, which enables our board of <font color="blue">directors</font> to <font color="blue">issue preferred</font>     stock  purchase  rights  that  would be <font color="blue">triggered by</font> an <font color="blue">acquisition</font> of     15 percent or more of the <font color="blue">outstanding shares</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions and <font color="blue">specific provisions</font> of <font color="blue">Minnesota </font>law relating to business     <font color="blue">combination</font>s with interested <font color="blue">stockholders</font> may have the effect of delaying,     deterring  or  preventing a merger or change in control</td>
    </tr>
    <tr>
      <td>Some of these     provisions  may discourage a future <font color="blue">acquisition</font> of our company even if     <font color="blue">stockholders</font> would receive an attractive value for their shares or if a     <font color="blue">significant</font> number of our <font color="blue">stockholders</font> believed such a proposed <font color="blue">transaction</font>     to be in their best interests</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">stockholders</font> who desire to     <font color="blue">participate</font> in such a <font color="blue">transaction</font> may not have the <font color="blue">opportunity</font> to do so</td>
    </tr>
  </tbody>
</table>